Clopidogrel: A Case for Indication-Specific Pharmacogenetics

被引：57

作者：

Johnson, J. A. ^{[1
,2
]}

Roden, D. M. ^{[3
,4
]}

Lesko, L. J. ^{[1
,2
]}

Ashley, E. ^{[5
]}

Klein, T. E. ^{[6
]}

Shuldiner, A. R. ^{[7
,8
]}

机构：

[1] Univ Florida, Coll Pharm, Gainesville, FL 32611 USA

[2] Univ Florida, Ctr Pharmacogenom, Gainesville, FL USA

[3] Vanderbilt Univ, Dept Med, Nashville, TN USA

[4] Vanderbilt Univ, Dept Pharmacol, Off Personalized Med, Nashville, TN USA

[5] Stanford Univ, Dept Med, Stanford, CA 94305 USA

[6] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[7] Univ Maryland, Sch Med, Program Personalized & Genom Med, Baltimore, MD 21201 USA

[8] Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, Baltimore, MD 21218 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷 / 05期

关键词：

CYP2C19; GENOTYPE; CLINICAL-EFFICACY; METAANALYSIS; OUTCOMES; THERAPY; RISK;

D O I：

10.1038/clpt.2012.21

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.

引用

页码：774 / 776

页数：3

共 10 条

[1] Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis [J].

Bauer, Tim ;

Bouman, Heleen J. ;

van Werkum, Jochem W. ;

Ford, Neville F. ;

ten Berg, Jurrien M. ;

Taubert, Dirk .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 343

[2] CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis [J].

Holmes, Michael V. ;

Perel, Pablo ;

Shah, Tina ;

Hingorani, Aroon D. ;

Casas, Juan P. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (24) :2704-2714

[3] Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects [J].

Hulot, Jean-Sebastien ;

Bura, Alessandra ;

Villard, Eric ;

Azizi, Michel ;

Remones, Veronique ;

Goyenvalle, Catherine ;

Aiach, Martine ;

Lechat, Philippe ;

Gaussem, Pascale .

BLOOD, 2006, 108 (07) :2244-2247

[4] Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration A Systematic Meta-Analysis [J].

Hulot, Jean-Sebastien ;

Collet, Jean-Philippe ;

Silvain, Johanne ;

Pena, Ana ;

Bellemain-Appaix, Anne ;

Barthelemy, Olivier ;

Cayla, Guillaume ;

Beygui, Farzin ;

Montalescot, Gilles .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (02) :134-143

[5] Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis [J].

Mega, Jessica L. ;

Simon, Tabassome ;

Collet, Jean-Philippe ;

Anderson, Jeffrey L. ;

Antman, Elliott M. ;

Bliden, Kevin ;

Cannon, Christopher P. ;

Danchin, Nicolas ;

Giusti, Betti ;

Gurbel, Paul ;

Horne, Benjamin D. ;

Hulot, Jean-Sebastian ;

Kastrati, Adnan ;

Montalescot, Gilles ;

Neumann, Franz-Josef ;

Shen, Lei ;

Sibbing, Dirk ;

Steg, P. Gabriel ;

Trenk, Dietmar ;

Wiviott, Stephen D. ;

Sabatine, Marc S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (16) :1821-1830

[6] Cytochrome P-450 Polymorphisms and Response to Clopidogrel. [J].

Mega, Jessica L. ;

Close, Sandra L. ;

Wiviott, Stephen D. ;

Shen, Lei ;

Hockett, Richard D. ;

Brandt, John T. ;

Walker, Joseph R. ;

Antman, Elliott M. ;

Macias, William ;

Braunwald, Eugene ;

Sabatine, Marc S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (04) :354-362

[7] Pharmacogenomics and Clopidogrel Irrational Exuberance? [J].

Nissen, Steven E. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (24) :2727-2728

[8] Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment [J].

Pare, Guillaume ;

Mehta, Shamir R. ;

Yusuf, Salim ;

Anand, Sonia S. ;

Connolly, Stuart J. ;

Hirsh, Jack ;

Simonsen, Katy ;

Bhatt, Deepak L. ;

Fox, Keith A. A. ;

Eikelboom, John W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1704-1714

[9] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy [J].

Scott, S. A. ;

Sangkuhl, K. ;

Gardner, E. E. ;

Stein, C. M. ;

Hulot, J-S ;

Johnson, J. A. ;

Roden, D. M. ;

Klein, T. E. ;

Shuldiner, A. R. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (02) :328-332

[10] Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy [J].

Shuldiner, Alan R. ;

O'Connell, Jeffrey R. ;

Bliden, Kevin P. ;

Gandhi, Amish ;

Ryan, Kathleen ;

Horenstein, Richard B. ;

Damcott, Coleen M. ;

Pakyz, Ruth ;

Tantry, Udaya S. ;

Gibson, Quince ;

Pollin, Toni I. ;

Post, Wendy ;

Parsa, Afshin ;

Mitchell, Braxton D. ;

Faraday, Nauder ;

Herzog, William ;

Gurbel, Paul A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (08) :849-858

← 1 →